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Summary
Objective: Angiogenesis is a process stimulated in inﬂamed synovium of patients with osteoarthritis (OA), and contributes to the progression of
the disease. Synovial ﬁbroblasts secrete angiogenic factors, such as vascular endothelial growth factor (VEGF), an up-regulator of angiogen-
esis, and this ability is increased by interleukin (IL)-1b. The purpose of this study was to verify whether IL-17 contributes and/or synergizes with
IL-1b and tumor necrosis factor (TNF)-a in vessel development in articular tissues by stimulating the secretion of proangiogenic factors by
synovial ﬁbroblasts.
Design: We stimulated in vitro synovial ﬁbroblasts isolated from OA, rheumatoid arthritis (RA) and fractured patients (FP) with IL-17 and IL-1b
and from OA patients with IL-17, IL-1b and TNF-a. In the supernatants from the cultures, we assayed the amount of VEGF by immunoassay
and other angiogenic factors (keratinocyte growth factor, KGF; hepatocyte growth factor, HGF; heparin-binding endothelial growth factor,
HB-EGF; angiopoietin-2, Ang-2; platelet-derived growth factor B, PDGF-BB; thrombopoietin, TPO) by chemiluminescence; semiquantitative
RT-PCR was used to state mRNA expression of nonreleased angiogenic factors (Ang-2 and PDGF-BB) and tissue inhibitors of metallopro-
teinase (TIMP)-1.
Results: IL-17, TNF-a and IL-1b increased VEGF secretion by synovial ﬁbroblasts from OA patients. IL-17 and IL-1b also increased VEGF
secretion in RA and FP. Besides, IL-17 increased KGF and HGF secretions in OA, RA and FP; in OA and RA, IL-17 also increased the
HB-EGF secretion and the expression of TIMP-1 as protein and mRNA. In OA patients IL-17 had an additive effect on TNF-a-stimulated
VEGF secretion.
Conclusions: These results suggest that IL-17 is an in vitro stimulator of angiogenic factor release, both by its own action and by cooperating
with TNF-a.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative multifactorial disease
with altered cartilage homeostasis, followed by synovial hy-
pertrophy and hyperplasia, with proliferation of lining cells
and subchondral bone alterations1. The synovium ﬁbro-
blast-like cells (synovial ﬁbroblasts) appear as cells activated
secondarily by cartilage modiﬁcation and do not show the
invasive peculiarities and the tumor-like morphology found
in rheumatoid arthritis (RA) patients1e6. However, in some
cases, the morphological feature of synovitis found in OA
can resemble that of RA, where synovial ﬁbroblasts are acti-
vated cells, which show proliferating properties5. In OA and
RA clinical symptoms, the synovial pannus feature, and the
progression of the disease are increasingly associated with
a synovium inﬂammation characterized by hypertrophy,
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Received 26 April 2005; revision accepted 12 October 2005.3proliferation of synovial cells, and also by the presence of
inﬁltrate in sublining tissue1,7. Angiogenesis, i.e., the forma-
tion of new capillaries from preexisting vessels, is a process
stimulated in joint tissues with chronic inﬂammation8, involv-
ing synoviumand cartilage, the latter normally avascular, and
its extent correlates with the progression of the disease6,9,10.
A wide panel of factors up- or down-regulates the vessel
proliferation and tissue invasion6. Many growth factors and
cytokines can up-regulate the vascularization processes by
directly inducing themigration and proliferation of endothelial
cells to determine the expansion of small vessels11,12, and
there are also indirect factors of angiogenesis, such as inter-
leukin (IL)-6 and IL-1b, which elicit their effects by inducing
tissue cells and/or attracting and inducing other cell types
to the site of inﬂammation to secrete angiogenic factors13e16.
Positive angiogenic factors are secreted by activated
connective tissue cells8,17,18. Finally, other soluble factors
mechanically facilitate or inhibit vascular growth and expan-
sion by acting on the tissue integrity. Among the latter, tissue
inhibitors of metalloproteinases (TIMPs) are modulated in
articular tissues from RA and OA patients and can control
angiogenesis by inhibiting the cartilage extracellular matrix
degradation carried out by proteolytic enzymes, such as
matrix metalloproteinases (MMPs)19,20.45
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most important up-regulators of angiogenesis, and pro-
motes endothelial cell migration and proliferation11. VEGF
is a 46e48 kDa glycosylated homodimeric polypeptide,
which has several variants. The main ones include 121,
145, 165, 189 and 206 amino acid isoforms. These isoforms
present different abilities to bind to extracellular matrix pro-
teoglycans and to VEGF receptors11. The expression of
VEGF has been demonstrated in synovial ﬂuid and mem-
brane of RA and OA patients21,22, and is produced by syno-
vial ﬁbroblasts and activated macrophages17,23.
We have recently demonstrated that proinﬂammatory
cytokines such as IL-1b, tumor necrosis factor (TNF)-a and
IL-17, over-expressed in articular RA and OA tissues1,24,
increase the secretion of VEGF by dedifferentiated chon-
drocytes25. It is known that IL-1b is also able to stimulate
the secretion of VEGF by human synovial ﬁbroblasts14,16,
while the effect of TNF-a is more debated14,16,26e28.
Thrombopoietin (TPO), keratinocyte growth factor (KGF),
heparin-binding endothelial growth factor (HB-EGF), plate-
let-derived growth factor B (PDGF-BB), hepatocyte growth
factor (HGF), and angiopoietin-2 (Ang-2) are also angiogen-
esis factors, which act directly and/or indirectly, by promot-
ing the secretion of VEGF, IL-6, or other growth factors,
which, in turn, stimulate endothelial cells to generate new
vessels6,15,29e31.
The aim of our study was to verify the effect of IL-17 alone
or in combination with IL-1b or TNF-a on articular tissue an-
giogenesis, by stimulating synovial ﬁbroblasts isolated from
OA patients to secrete VEGF, and to see whether IL-17 can
also stimulate the secretion of other positive or negative
regulators of angiogenesis. The effect of IL-17 was also
evaluated on synovial ﬁbroblasts isolated from patients
with RA and from patients who had undergone arthroplasty
due to fracture.
Materials and methods
TISSUE SAMPLES AND PATIENTS
Synovial samples were obtained from patients with OA
and RA undergoing knee or hip replacement surgery: 19 pa-
tients with OA (mean age 65 years, range 44e80 years)
(eight knees and 11 hips). Diagnosis of OA was based on
clinical, radiological and laboratory parameters32 and all
OA patients involved in the study showed grade IIIeIV radio-
logical features according to the Kellgren and Lawrence
grading system33. For comparison, human synovium was
obtained from four femoral heads and one tibial plateau re-
moved after fracture in patients with no history of articular
morphological and histological alterations of OA or RA (FP)
(mean age 68 years, range 60e81 years) and from seven
patients with RA (mean age 61 years, range 24e78 years)
(four knees and three hips) who had undergone arthroplasty.
Diagnosis of RAwasmade according to AmericanCollege of
Rheumatology criteria34. The study was approved by the
ethical committee of Istituti Ortopedici Rizzoli and informed
consent was obtained from the patients.
ISOLATION OF SYNOVIAL FIBROBLASTS
Specimens of synovial tissue were cut into small pieces
(not more than 1 mm2) and seeded in 25-cm2 culture ﬂasks
in Optimem-1 (Gibco BRL) supplemented with 200 mg/ml of
gentamycin (Flow Laboratories, Biaggio, Switzerland), 15%
heat inactivated fetal calf serum (FCS) (Gibco BRL)(complete medium) at 37(C in 5% CO2 humidiﬁed atmo-
sphere, as previously described35. After about 15 days,
when adherent cells from synovium pieces were at conﬂu-
ence, they were split by 0.05% trypsin/0.5 mM ethylenedia-
minetetraacetic acid (EDTA) (Sigma, St. Louis, MO, USA),
washed and passaged into a 75 cm2 ﬂask (T 75). When
synovial ﬁbroblasts seeded in T 75 culture ﬂask were con-
ﬂuent, they were tripsinized and split 1:3 to obtain subse-
quent passages. Synovial ﬁbroblasts were used between
passages 3 and 8. At these passages synovial ﬁbroblasts
were phenotypically analyzed by a ﬂow cytometer FACStar
Plus (Becton Dickinson, St Diego, CA, USA) as previously
described35 and appeared as a homogeneous population.
CELL STIMULATION FOR ANGIOGENESIS FACTOR RELEASE
Synovial ﬁbroblasts were cultured in a 96-well ﬂat bottom
microplate in 0.2 ml of complete medium (1 104 cells/well).
After overnight culture, 0.1 ml was substituted with 0.1 ml of
complete medium with or without stimuli: 50 ng/ml recombi-
nant human (rh) IL-17 (IL-17) (R&D Systems, MN, USA),
100 U/ml rhIL-1b (IL-1b; speciﬁc activity 5 107 U/mg)
(Boehringer, Mannheim, Germany), and 100 U/ml rhTNF-a
(TNF-a; speciﬁc activity 1 108 U/mg) (Boehringer) (ﬁnal
concentration). Synovial ﬁbroblasts were also stimulated
with IL-17 added to different doses of IL-1b or TNF-a, as
described for each experiment. After 72 h incubation, super-
natants were collected and maintained at 80(C until their
use. Stimulus concentration and incubation time were
chosen on the basis of our previous experience with these
cells and these cytokines25,35, mainly to obtain detectable
amounts of not highly expressed soluble factors or optimal
stimulation with TNF-a, which was a slower stimulus in com-
parison to IL-1b and IL-17 (data not shown). Fibroblasts
from three OA patients were also cultured in complete
medium for 10 h, then the complete medium was substituted
with medium without FCS and, after 24 h incubation, stimuli,
diluted in medium without serum, were added as above
described.
CELL STIMULATION FOR SEMIQUANTITATIVE RT-PCR
Synovial ﬁbroblasts from ﬁve patients with OA were cul-
tured in 6-well tissue culture plates in 4 ml of complete me-
dium (2 105 cells/well). After overnight culture, 2 ml was
substituted with 2 ml of complete medium without or with
stimuli: 50 ng/ml IL-17 (R&D Systems). After 5 h incubation,
the supernatant was removed, the cells tripsinized, counted
and the total cellular RNA was isolated with RNAwiz (Am-
bion, Austin, TX, USA) following the manufacturer’s instruc-
tions, and maintained at 80(C until its use.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
FOR VEGF AND TPO
VEGF and TPO secreted by nonstimulated and stimulated
synovial ﬁbroblasts were determined in the supernatant of
72 h culture by an ELISA with R&D Systems’ reagents.
VEGF concentrations were evaluated using 0.4 mg/ml of
capture antibody and 0.2 mg/ml of detecting antibody, fol-
lowing the manufacturer’s recommended protocol. These
antibodies recognize VEGF121, VEGF165 and naturally-
occurring human VEGF; so, most of the VEGF detected in
our samples was VEGF121, the secreted isoform, soluble
and not binding heparan sulfate or extracellular matrix11.
The detection limit was 15 pg/ml. Streptavidin-HRP (Phar-
Mingen), diluted 1:1000, was used for the assay described,
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tems). Absorbance was measured at 450 nm, corrected by
reading at 540 nm, by an ELISA reader (Labsystems,
Helsinki, Finland). TPO concentrations were evaluated by
a Quantikine for human TPO, following the manufacturer’s
recommended protocol. The detection limit was 15 pg/ml.
CHEMILUMINESCENCE ARRAY FOR PROANGIOGENIC
FACTORS AND TIMP-1
The Ang-2, HB-EGF, HGF, KGF, PDGF-BB and TIMP-1
concentrations were evaluated all together in the same
sample by a SearchLight kit for Human Angiogenesis Ar-
ray (Pierce Biotechnology, Rockford, IL, USA), following the
manufacturer’s recommended protocol. The method is
a sandwich ELISA test for multiple determinations, which
utilizes a chemiluminescent substrate. The luminescent sig-
nal produced by enzymeesubstrate reaction was detected
with a SearchLight cooled CCD camera (Pierce Endogen,
Woburn, MA 01801, USA). The detection limit was 20.6
pg/ml (Ang-2 and TIMP-1), 7.7 pg/ml (HB-EGF), 6.6 pg/ml
(HGF) and 4.1 pg/ml (KGF and PDGF-BB).
SEMIQUANTITATIVE RT-PCR
Onemicrogram of total RNA per sample was reverse-tran-
scribed using Moloney murine leukemia virus reverse tran-
scriptase (RT) (Perkin Elmer, Norwalk, CT, USA) and
random examer priming, according to the manufacturer’s
protocol (Perkin Elmer). One hundred nanograms of the
various cDNAs was used in the subsequent ampliﬁcation
reactions. U937 cell line stimulated for 5 h with ionomycin
(0.5 mM)/phorbol-myristate-acetate (PMA) (15 ng/ml)/lipo-
polysaccharide from E. coli (LPS) (0.5 mM) (Sigma) or PMA
(10 ng/ml)/LPS (1 mg/ml) for Ang-2 and PDGF-B, respectively,
and knee synovial ﬁbroblasts from a subject with RA, for
TIMP-1, were used as positive controls. Polymerase chain
reaction (PCR) primers for Ang-2, PDGF-B and TIMP-1
were generated using the Light Cycler Probe Design Soft-
ware (Roche Applied Science, Mannheim, Germany) from
the Genbank sequences AF004327, NM_002608 and
NM_003254, respectively, in order to span exons to discrim-
inate ampliﬁcation of genomic DNA, possibly contaminating
RNA preparations: Ang-2 forward, 5#-CAAAGGATGGAGA
CAACG-3#; Ang-2 reverse, 5#-CTTGAGCGAATAGCCTG-3#;
PDGF-B forward, 5#-GGTGACCATTCGGACG-3#; PDGF-B
reverse, 5#-GGGCAATACAGCAAATACCA-3#; TIMP-1 for-
ward, 5#-CACCAAGACCTACACTG-3#; TIMP-1 reverse,
5#-GTGACGGGACTGGAAG-3#. Primers for the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), used as endogenous control, were GAPDH
forward, 5#-TGGTATCGTGGAAGGACTCATGAC-3# and
GAPDH reverse, 5#-ATGCCAGTGAGCTTCCCGTTCAGC-
3#. Real-time PCR for each transcript was performed using
the QuantiTect SYBR Green PCR kit (QIAGEN GmbH, Hil-
den, Germany) in 20 ml ﬁnal volume with 0.5 mM of each
primer, 4.5 mM (Ang-2), 3.5 mM (PDGF-B) or 2.5 mM
(TIMP-1 and GAPDH) MgCl2, in a Light Cycler instrument
(Roche Molecular Biochemicals, Mannheim, Germany)
with the following protocols: initial activation of HotStart
Taq DNA polymerase at 95(C for 15 min; 55 cycles (Ang-2
and PDGF-B) or 40 cycles (TIMP-1 and GAPDH) at: 94(C
for 15 s; 55(C for 25 s (Ang-2) or 55(C for 15 s (PDGF-B
and TIMP-1) or 60(C for 20 s (GAPDH); 72(C for 15 s
(Ang-2, TIMP-1 and GAPDH) or 72(C for 25 s (PDGF-B).
The crossing point values were determined for each sample
and speciﬁcity of the amplicons was conﬁrmed by meltingcurve analysis. To determine absolute GAPDH mRNA
copy number, a standard curve was generated using
10-fold dilution series of gel-puriﬁed PCR products ranging
from 6 106 to 6 102 copies. Ampliﬁcation efﬁciencies
for Ang-2, PDGF-B and TIMP-1, as calculated from the
slopes of log input amounts plotted vs crossing point values,
were conﬁrmed to be high and comparable with GAPDH am-
pliﬁcation efﬁciency (differences varied between 2.2 and
3.2%). Relative mRNA expressions of Ang-2, PDGF-B and
TIMP-1 were obtained by normalization to GAPDH by the
formula ð1þ EÞDCT 36, where E represents the reaction efﬁ-
ciency (approximated to 1 because >90% for all the tran-
scripts) and DCT, the difference between the GAPDH and
the speciﬁc crossing point for each sample.
STATISTICAL ANALYSIS
Nonparametric tests were used for statistical analysis of
the results: differences between groups were analyzed by
the ManneWhitney U test and when the Friedman analysis
of variance (ANOVA) test for multiple comparison was sig-
niﬁcant, paired data were analyzed by the Wilcoxon
matched-pairs test.
Results
EFFECT OF IL-17, IL-1b AND TNF-a ON THE SECRETION OF
VEGF, TPO, KGF, HGF, HB-EGF AND TIMP-1 BY SYNOVIAL
FIBROBLASTS
Fibroblasts isolated from synovium of OA, RA and FP pa-
tients maintained in culture with complete medium alone for
72 h (basal conditions) released VEGF, without differences
among the groups (Fig. 1). IL-17 and IL-1b were able to
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Fig. 1. Production of VEGF by synovial ﬁbroblasts. Data are repre-
sented from synovial ﬁbroblasts of ﬁve subjects with fractures (FP),
seven RA subjects and 19 OA subjects. Results are expressed as
pg/ml of VEGF secreted by synovial ﬁbroblasts after 72 h culture
under nonstimulated conditions (NS, white boxes), with IL-17
(50 ng/ml, hatched boxes), IL-1b (100 U/ml, light gray boxes) or
TNF-a (100 U/ml, dark gray box, nine OA subjects). The symbols
show the medians, the boxes show 25th and 75th percentiles,
and the vertical lines below and above the boxes show 10th and
90th percentiles. Statistical comparison between nonstimulated
and stimulated conditions of each group was made using the Wil-
coxon matched-pairs test, and the ManneWhitney U test was
used to compare the different groups. *P< 0.05 and **P< 0.01
vs NS control of the same group.
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blasts and showed comparable activity (Fig. 1). The sti-
mulation of synovial ﬁbroblasts from OA patients with
TNF-a signiﬁcantly increased the spontaneous release of
VEGF compared to nonstimulated controls, such as the
stimulation with IL-17 and IL-1b (Fig. 1). As we expected,
in the absence of FCS, similar but reduced levels were ob-
tained: the constitutive release of VEGF by synovial ﬁbro-
blasts from three OA patients was (mean SD) 51 28%
lower than that in complete medium. The enhancing effects
of IL-17, IL-1b and TNF-a, evaluated as relative increase,
were lower than those obtained in complete medium, but
signiﬁcant (P< 0.05 vs nonstimulated control), with mean
VEGF level increases of 1.8-fold, 2.2-fold and 1.3-fold, re-
spectively, compared to 2.2-fold, 2.4-fold and 1.6-fold.
This result may depend on the presence of some factors
that induce VEGF production in FCS.
Spontaneous secretion of TPO by synovial ﬁbroblasts
was very low (range 20e54 pg/ml) and limited to nine of
23 (39%) OA, RA and FP patients, independently of the
group studied. Similar results were obtained after stimula-
tion with IL-17, IL-1b and TNF-a that could weakly modulate
the TPO secretion in only some subjects from each group
(OA, RA and FP) (data not shown).
Synovial ﬁbroblasts fromOA, RA and FP, secreted detect-
able amounts of KGF, HGF, and HB-EGF [Fig. 2(aec)]. Inter-
estingly, the amount of these angiogenic factors secreted
by FP synovial ﬁbroblasts tended to be higher than that se-
creted by RA and OA synovial ﬁbroblasts, with signiﬁcant
differences for KGF andHB-EGF. The stimulation of synovial
ﬁbroblasts from RA and OA patients with IL-17 increased the
spontaneous release of KGF, HGF and HB-EGF compared
to nonstimulated controls. In FP patients, IL-17 increased
the secretion of KGF and HGF, but not the release of
HB-EGF. The effect of IL-17 seems to be mainly evident
on synovial ﬁbroblasts from subjects with important inﬂam-
matory components. In fact, when we compared the cytokine
relative increase of each angiogenic factor after IL-17 stimu-
lation between the different groups of subjects, we observed
that IL-17 increased the release of KGFmore on RA synovial
ﬁbroblasts than on FP and OA synovial ﬁbroblasts
(P¼ 0.009 and P¼ 0.003, respectively) [Fig. 2(a)]. More-
over, HGF release was increased more in RA than in OA
synovial ﬁbroblasts (P¼ 0.048) [Fig. 2(b)]; HB-EGF release
was also increased more in OA than in FP synovial ﬁbro-
blasts (P¼ 0.048) [Fig. 2(c)]. This analysis was performed
by the ManneWhitney U test.
Besides, synovial ﬁbroblasts from all subjects secreted
high amounts of TIMP-1, both under basal conditions, as
expected, and after IL-17 stimulation. Nonstimulated sam-
ples with measurable, not very high, amounts of TIMP-1
are represented in Table I. The effect of IL-17 treatment
tended to be stimulating but measurable only in one OA
and three RA cases (Table I), in which the TIMP-1 level
after IL-17 stimulation was not over-scale.
IL-17 MODULATION OF mRNA SPECIFIC FOR ANG-2, PDGF-B
AND TIMP-1
Since chemiluminescence array did not show detectable
levels of Ang-2 and PDGF-BB in the supernatants, either
from nonstimulated or IL-17-stimulated cultures, the possi-
ble IL-17 modulation of Ang-2 and PDGF-B mRNA expres-
sion was evaluated by real-time RT-PCR in synovial
ﬁbroblasts from four OA subjects. Synovial ﬁbroblasts
from three subjects incubated under basal conditions
showed a very light signal for PDGF-B speciﬁc mRNA(relative expression range 0.1 105 to 2.04 105),
which was more evident, but not signiﬁcantly, after stimula-
tion with IL-17. In one case, we did not observe the expres-
sion of PDGF-B speciﬁc mRNA, even in IL-17-stimulated
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Fig. 2. Release of KGF (a), HGF (b) and HB-EGF (c) by synovial ﬁ-
broblasts after 72 h of incubation in nonstimulated conditions (NS,
white boxes) or with IL-17 (50 ng/ml, hatched boxes). Synovial ﬁbro-
blasts were isolated from ﬁve subjects with fracture (FP), ﬁve sub-
jects with RA and nine subjects with OA. The symbols show the
medians, the boxes show 25th and 75th percentiles, and the vertical
lines below and above the boxes show 10th and 90th percentiles.
Statistical comparison between nonstimulated and stimulated condi-
tions of each group was made using the Wilcoxon matched-pairs
test, and the ManneWhitney U test was used to compare the differ-
ent groups. *P< 0.05 and **P< 0.01 vs NS control of the same
group. xP< 0.05 and xxP< 0.01 vs NS of FP group.
349Osteoarthritis and Cartilage Vol. 14, No. 4cells. The maximum increment obtained was 2.4-fold, while
nonstimulated U937 cells had PDGF-B mRNA relative ex-
pression of 0.98 105 with an increment of 4.4-fold after
stimulation. Similarly, Ang-2 speciﬁc mRNA was detectable
in all subjects, although poorly expressed (relative expres-
sion range 1.76 105 to 2.15 105), but without signiﬁ-
cant modulation after IL-17 treatment. Nonstimulated U937
cells did not express Ang-2 mRNA, while after stimulation
the relative expression was 16.84 105. Also for TIMP-1,
whose expression was very high in the supernatants, and
in most cases the enhancing effect of IL-17 was not measur-
able, speciﬁc IL-17 mediated mRNA modulation was evalu-
ated by real-time RT-PCR. TIMP-1 speciﬁc mRNA was
highly expressed in all synovial ﬁbroblasts tested and was
up-regulated by IL-17 in three of four cases (Fig. 3).
Case 1 (Fig. 3) also showed high amounts of TIMP-1 protein
in the supernatant, positively modulated by IL-17 treatment
(case 6, Table I).
Table I
Secretion of TIMP-1 by synovial fibroblasts. Data are represented
from nonstimulated samples with measurable amounts of TIMP-1:
one of five subjects with fracture (FP), five of nine subjects with
OA and four of five subjects with RA. Cells were incubated 72 h in
medium alone (NS) or in the presence of IL-17 (50 ng/ml). All other
nonstimulated and IL-17-stimulated samples secreted over-scale
amounts of TIMP-1
TIMP-1 (pg/ml)
Case Disease NS IL-17 S.I.*
1 FP 15,920 >33,000y >2.0
2 OA 24,457 >33,000y >1.4
3 OA 143,000 >167,000y >1.2
4 OA 15,705 25,367 1.61
5 OA 137,292 >167,000y >1.2
6 OA 137,748 >167,000y >1.2
7 RA 7,231 72,775 10.06
8 RA 139,388 >167,000y >1.2
9 RA 89,295 102,286 1.15
10 RA 41,577 49,546 1.19
*Stimulation index: ratio between TIMP-1 release by IL-17-stim-
ulated cells and TIMP-1 release by cells cultured under basal con-
ditions (NS).
yOver-scale sample.
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Fig. 3. Relative expression of TIMP-1-speciﬁc mRNA by real-time
RT-PCR in synovial ﬁbroblasts from four subjects with OA. Relative
TIMP-1 expression was obtained by normalization to GAPDH
mRNA (see Materials and methods) in synovial ﬁbroblasts after
5 h culture under nonstimulated conditions (NS, light gray boxes)
and stimulated with IL-17 (50 ng/ml, dark gray boxes). Case 1 cor-
responds to case 6 in Table I.EFFECT OF IL-17 ON VEGF SECRETION STIMULATED BY IL-1b
OR TNF-a
We also investigated the combined effect of IL-17 with IL-
1b or TNF-a on VEGF secretion. Synovial ﬁbroblasts from
ﬁve OA patients were utilized to control the additional effect
of IL-17 on cultures stimulated with various concentrations
of IL-1b or TNF-a, as speciﬁed (Fig. 4).
IL-17 did not affect the release of VEGF stimulated by IL-
1b, at any of the concentrations tested, but the additional
presence of IL-17 in cultures stimulated with TNF-a was
able to induce a higher secretion of VEGF, in comparison
with the stimulation with TNF-a alone. This increment was
signiﬁcantly higher only at the highest concentration of
TNF-a. IL-17 and TNF-a had an additive, nonsynergistic ef-
fect and, moreover, the amount of VEGF was lower than the
sum of the amounts stimulated by IL-17 and TNF-a alone
(Fig. 4).
Discussion
IL-17 has been recently described as a proinﬂammatory
cytokine secreted by T-activated lymphocytes (reviewed
by Gaffen37). This cytokine is over-expressed in OA and
RA joint tissues, and, although the precise site of IL-17 pro-
duction is still unclear, it may be considered as a factor that
contributes, with IL-1b and TNF-a, to the pathogenesis of
rheumatic diseases1. Recently, we have reported that syno-
vial ﬁbroblasts and chondrocytes from OA patients express
the receptor of IL-1735, and we have described the stimulat-
ing effect of IL-17 in vitro on dedifferentiated chondrocytes
to secrete VEGF25. IL-17 might contribute to the angiogen-
esis in OA articular tissues. VEGF was detected in vivo in
synovial ﬂuid of OA and RA subjects and, in lower amounts,
in other forms of arthritis. Besides, OA and RA synovial
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Fig. 4. Effect of IL-17 on the secretion of VEGF by synovial ﬁbro-
blasts costimulated with IL-1b or TNF-a. Results are represented
as the median (symbols) of pg/ml of VEGF secreted by synovial ﬁ-
broblasts obtained from ﬁve subjects with OA and incubated 72 h
under basal conditions (NS), with IL-17 (50 ng/ml), IL-1b (100 U/ml),
TNF-a (100 U/ml) or IL-17 combined with IL-1b or TNF-a at various
concentrations, as indicated in the graph (1-10-100 U/ml). The box-
es show 25th and 75th percentiles, and the vertical lines below and
above the boxes show 10th and 90th percentiles. Statistical com-
parison between nonstimulated and stimulated conditions of each
group was made using the Wilcoxon matched-pairs test, and the
ManneWhitney U test was used to compare the different groups.
*P< 0.05 and **P< 0.01 vs NS controls; xP< 0.05 vs IL-17, IL-
1b and TNF-a alone.
350 M. C. Honorati et al.: IL-17 and angiogenic factor releasetissues exhibited VEGF positive cells, which were very rare
in normal synovial tissues38. Normal human synovial ﬁbro-
blasts secrete in vitro lower levels of VEGF than RA or
OA synovial ﬁbroblasts14. This evidence supports the role
of VEGF in promoting angiogenesis in the synovium. We
found that not only IL-1b14,16,27, but also IL-17 and TNF-a in-
crease VEGF secretion by synovial ﬁbroblasts from OA, RA
and FP patients. Previously it had been shown that the ef-
fect of TNF-a might be undetectable up to 24e48 h of incu-
bation, or depending on the culture conditions, such as cell
density, and mainly, the cell source14,16,26,27,39,40.
The effect of the TNF-a-stimulated VEGF secretion was
enhanced by IL-17, which had no effect on IL-1b stimulated
cells. The amount of VEGF secreted after stimulation with IL-
17 plus TNF-a never exceeded the sum of the amounts stim-
ulated by IL-17 and TNF-a separately. Therefore, it seems
that in our experimental model IL-17 exerted an additive
but not synergistic effect on TNF-a. It may be hypothesized
that the link of IL-17 and TNF-a to their own receptor on sy-
novial ﬁbroblasts activates the synthesis of VEGF by inde-
pendent metabolic pathways, because of the additive
effect of these two cytokines, whereas IL-17 and IL-1b prob-
ably utilize activation pathways that interfere with each other.
Recent studies have demonstrated that VEGF expression is
regulated by the activation of transcription nuclear factor-kB
(NF-kB)41. IL-17, IL-1b and TNF-a, asmany inﬂammatory cy-
tokines, can modulate the gene expression by NF-kB, al-
though it is known that IL-17 can also utilize other signaling
pathways37,42. So, the cytokine-stimulating effect might de-
pend on the combination of the signal transduction and tran-
scription pathways utilized by the cytokine target cells.
Interestingly, synovial ﬁbroblasts from subjects with frac-
tures (FP) constitutively secreted VEGF in vitro, and in
amounts comparable to those found in OA and RA, although
these subjects did not present any articular morphological al-
terations. It is likely that VEGF secretion in FP patients is
a self-limited phenomenon related to the posttrauma inﬂam-
mation, in accordance with the presence of some biochemi-
cal parameters of inﬂammation, such as elevated level of
protein C reactive and erytrocyte sedimentation rate (VES)
in the patients included in this study, and our observations
of the presence of IL-1b and TNF-a positive chondrocytes
in posttraumatic patients43.
Although VEGF seems to be one of the most important in-
ducers of vessel proliferation, and is also one of the most
widely studied, there are many different growth factors in-
volved in angiogenesis. We previously showed that IL-17
can increase IL-8 release by synovial ﬁbroblasts from OA
patients35. IL-8 is a chemokine able to stimulate the prolifer-
ation of endothelial cells44,45. In accordance with these
ﬁndings, IL-17 can up-regulate the constitutive release of
other important angiogenesis factors, such as KGF, HGF
and HB-EGF by synovial ﬁbroblasts. KGF, mainly produced
by stromal cells, is a growth factor that activates many types
of cells. Interestingly, KGF only carries out its effect on the
microvascular endothelial cells, thus stimulating their prolif-
eration, chemotaxis, and barrier maintenance30. HGF is an
endothelial cell-speciﬁc growth factor which can stimulate
the endothelial cell proliferation more potently than other
angiogenic factors, such as basic ﬁbroblast growth factor
(b-FGF), VEGF and IL-6; moreover, its effect is additive
with b-FGF46. HB-EGF is a direct/indirect angiogenic factor,
being able to stimulate the proliferation of microvascular
endothelial cells and vessel smooth muscle cells and the
secretion of VEGF andmetalloproteinases47e49. It is not sur-
prising that synovial ﬁbroblasts from FP subjects released
higher amounts of HGF than RA and OA synovial ﬁbroblastsat basal culture conditions, because HGF is present in nor-
mal synovial tissues, and the percentages of HGF-positive
ﬁbroblasts seem to be higher in normal samples than in RA
and OA synovial specimens50,51. In this study cultured syno-
vial ﬁbroblasts appeared to maintain the same phenotype as
in vivo, releasing more HGF when isolated from nonarthritic
than from arthritic tissues. Because it is not known whether
there are KGF- and HB-EGF-positive cells in synovial mem-
brane, or whether synovial ﬁbroblasts can release these fac-
tors, KGF and HB-EGF could be released by cultured
synovial ﬁbroblasts in a similar way to HGF. So, IL-17 ap-
pears as an in vitro potent proangiogenic cytokine.
In addition, we have shown that synovial ﬁbroblasts, cul-
tured in the presence of IL-17, increased their constitutive
TIMP-1 expression. TIMP-1 can be deﬁned as an inhibitor
of angiogenesis, having MMPs inhibitory activity52. It has
also been shown that TIMP-1 inhibits migration and tubular
formation in vitro by microvascular endothelial cells53,54.
Our ﬁndings are not surprising, because TNF-a is also
able to stimulate both VEGF and TIMP-1 by synovial ﬁbro-
blasts28. The possible increasing effect of IL-17 on TIMP-1
expression by OA synovial ﬁbroblasts could represent
a model of autoregulation: IL-17 could dampen its own ex-
cessive proangiogenic activity by also stimulating the secre-
tion of soluble factors able to oppose the angiogenesis.
Although IL-17 can up-regulate several main angiogenic
factors, in our experimental model this cytokine seems un-
able to stimulate the expression of TPO, PDGF-BB and
Ang-2, and appears as a proangiogenic cytokine able to
stimulate a limited panel of angiogenic factors, thus improv-
ing more than inducing their gene expression.
In conclusion, our ﬁndings support the hypothesis that IL-
17 is an important factor coresponsible for the pathogenesis
of OA and RA, but further studies are necessary to under-
stand the ﬁne mechanisms utilized by this cytokine to iden-
tify new therapeutic targets to control inﬂammation and
angiogenesis.
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